All In Biotech

Drug Trial Radar · NCT04817007

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Mar 22, 2021

Primary completion

Aug 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.

Conditions

  • Myelofibrosis

Interventions

  • BMS-986158Drug

    Specified dose on specified days

  • RuxolitinibDrug

    Specified dose on specified days

  • FedratinibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: Up to 52 months
  2. Incidence of serious adverse events (SAEs)Time frame: Up to 52 months
  3. Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteriaTime frame: Up to 26 months
  4. Incidence of AEs leading to discontinuationTime frame: Up to 52 months
  5. Incidence of deathTime frame: Up to 52 months

Locations

49 sites in 11 countries. Site status is shown where the registry gives one.

  • Local Institution - 0069

    Newport Beach, California

  • Local Institution - 0090

    Lake Mary, Florida

  • Local Institution - 0043

    New Orleans, Louisiana

  • Local Institution - 0038

    Worcester, Massachusetts

  • Local Institution - 0033

    Ann Arbor, Michigan

  • Local Institution - 0045

    Hackensack, New Jersey

  • Local Institution - 0076

    Chapel Hill, North Carolina

  • Local Institution - 0042

    Pittsburgh, Pennsylvania

  • Local Institution - 0036

    Blacktown, New South Wales, Australia

  • Local Institution - 0032

    Wollongong, New South Wales, Australia

  • Local Institution - 0007

    East Melbourne, Victoria, Australia

  • Local Institution - 0006

    Heidelberg, Victoria, Australia

  • Local Institution - 0041

    Nedlands, Western Australia, Australia

  • Local Institution - 0015

    West Perth, Western Australia, Australia

  • Local Institution - 0030

    Brest, France

  • Local Institution - 0008

    Marseille, France

  • Local Institution - 0027

    Nice, France

  • Local Institution - 0011

    Paris, France

  • Local Institution - 0010

    Villejuif, France

  • Local Institution - 0068

    Erding, Bavaria, Germany

  • Local Institution - 0039

    Essen, North Rhine-Westphalia, Germany

  • Local Institution - 0040

    Chemnitz, Saxony, Germany

  • Local Institution - 0035

    Halle, Saxony-Anhalt, Germany

  • Local Institution - 0050

    Lübeck, Schleswig-Holstein, Germany

  • Local Institution - 0061

    Chaïdári, Attikí, Greece

  • Local Institution - 0047

    Thessaloniki, Thessaloníki, Greece

  • Local Institution - 0016

    Jerusalem, Israel

  • Local Institution - 0018

    Petah Tikva, Israel

  • Local Institution - 0017

    Ramat Gan, Israel

  • Local Institution - 0019

    Tel Aviv, Israel

  • Local Institution - 0086

    Beersheba, Southern District, Israel

  • Local Institution - 0003

    Bologna, Italy

  • Local Institution - 0002

    Brescia, Italy

  • Local Institution - 0001

    Florence, Italy

  • Local Institution - 0012

    Verona, Italy

  • Local Institution - 0062

    Gdansk, Poland

  • Local Institution - 0077

    Słupsk, Pomeranian Voivodeship, Poland

  • Local Institution - 0083

    Bucharest, Romania

  • Local Institution - 0051

    Cluj-Napoca, Romania

  • Local Institution - 0052

    Bucuresti, Cluj, Romania

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.